EndoStim
EndoStim is a pre-commercial medical device company developing an implantable neurostimulation system that delivers automatic electrical stimulation to the lower esophageal sphincter to treat drug refractory GERD in patients who fail proton pump inhibitor therapy.
- Company typePrivate
- Founded2009
- HeadquartersSt Louis, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What EndoStim does
EndoStim, Inc. is a privately held, pre-commercial medical device company headquartered in Santa Ana, California, developing a first-in-class implantable neurostimulation system for drug refractory gastroesophageal reflux disease (GERD). The company's core product, the EndoStim System, consists of an implantable neurostimulator connected to two electrodes placed on the lower esophageal sphincter (LES) via a minimally-invasive laparoscopic procedure of approximately one hour. The device automatically delivers mild, sub-sensory electrical signals throughout the day to restore normal LES function, thereby preventing reflux while preserving the patient's natural anatomy and avoiding the gastrointestinal side effects typical of conventional anti-reflux surgery. The system is programmed wirelessly by physicians via an external handheld controller and is designed with a battery life of approximately six years under recommended stimulation algorithms.
EndoStim has built a substantial clinical evidence base, including peer-reviewed publications in Gastroenterology and Surgical Endoscopy, a double-blinded, sham-controlled pivotal trial (LESS-GERD / NCT02749071), and a multicenter commercial patient registry with up to five years of follow-up demonstrating sustained symptom control, reduced PPI dependence, and improved sleep quality. The company received FDA Breakthrough Device Designation in October 2022 and concluded a pre-submission meeting with the FDA in January 2023, with a Premarket Approval (PMA) filing intended to follow. The EndoStim System is currently not approved for sale in the US (limited to investigational use) and is not commercially available in the EU or Latin America, although international clinical studies have been conducted in those regions.
The revenue model is anticipated to be hardware sales of the implantable system, supplemented by procedural/implant-related revenue, distributed directly to gastroenterologists and surgeons once commercial clearance is obtained. EndoStim has funded development through venture capital, with disclosed rounds totaling approximately $79.6 million across 2009–2018 from investors including Prolog Ventures, Sante Ventures, Endeavour Vision, Gimv, Wellington Partners, Vectis Healthcare, and Billiken Angels Network. The company is led by CEO Eric B. Goorno (appointed February 2022, formerly of Boston Scientific), with founder Dr. Virender K. Sharma serving as Chief Medical Officer.
EndoStim firmographics
Firmographics- Name
- EndoStim
- Legal name
- EndoStim, Inc.
- Website
- https://endostim.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- EndoStim is a pre-commercial medical device company developing an implantable neurostimulation system that delivers automatic electrical stimulation to the lower esophageal sphincter to treat drug refractory GERD in patients who fail proton pump inhibitor therapy.
- Ownership category
- akta.pro rank
EndoStim industry classification
Industry- Product category
- Implantable Neurostimulation Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- General Gastroenterology (HLAKAEAA)
- akta.pro secondary industry
- Endoscopy & GI Procedure Centers (HLAFAIAE)
Keywords
Where EndoStim is headquartered
LocationHeadquarters
- HQ city
- St Louis
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
EndoStim business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Marketing or Sales, Personnel
Revenue model
- Medical Device Sales: EndoStim is a medical device company developing and commercializing a first-in-class neurostimulation treatment system. As an implantable medical device, the revenue model would likely involve device sales and potentially associated procedural/instrument revenue. The product is not yet commercially available while pursuing FDA approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
EndoStim product offering
Product offeringCore offering
EndoStim develops the EndoStim System, a first-in-class implantable neurostimulation device that automatically delivers mild electrical signals throughout the day to the lower esophageal sphincter (LES) muscle to restore normal function and provide long-term reflux control for patients with drug refractory gastroesophageal reflux disease (GERD). The system is placed via a minimally-invasive laparoscopic procedure of approximately 1 hour, with 2 small electrodes on the lower esophagus and a neurostimulator positioned under the skin in the abdomen, and is programmed wirelessly by a physician using an external handheld controller. The device is not yet approved for sale in the US (limited to investigational use only) and is not commercially available in the EU or Latin America.
Product overview
EndoStim is a medical device company developing a first-in-class neurostimulation treatment system for drug refractory gastroesophageal reflux disease (GERD). The company's core product is the EndoStim System, an implantable neurostimulation device that consists of an implantable neurostimulator and lead placed via minimally-invasive laparoscopic procedure. The system is paired with EndoStim LES Stimulation Therapy, which delivers mild electrical signals to the lower esophageal sphincter (LES) muscle throughout the day. The EndoStim System is programmed wirelessly by a physician using an external handheld controller. The therapy is designed to restore normal esophageal function while preserving the body's natural anatomy to avoid typical gastrointestinal side effects of traditional anti-reflux surgery. The EndoStim System is not yet commercially available in the US (limited to investigational use only) and not commercially available in the EU or Latin America.
Differentiator
Problem solved
Functional benefit
Products and services
- EndoStim System An implantable neurostimulation device system consisting of an implantable neurostimulator and leads placed via minimally-invasive laparoscopic procedure (approximately 1 hour with 2 small electrodes on the lower esophagus). It is designed to deliver mild electrical signals throughout the day to the lower esophageal sphincter (LES) muscle to restore normal function and provide long-term reflux control for drug refractory GERD patients. The device is programmed wirelessly by a physician using an external handheld controller, with an expected battery life of approximately six years under recommended stimulation algorithms.
- EndoStim LES Stimulation Therapy A first-in-class neurostimulation treatment that automatically delivers mild electrical signals throughout the day to the patient's weak or dysfunctional lower esophageal sphincter (LES) muscle. The stimulation is designed to restore normal LES function — staying closed to prevent reflux and opening to allow food and drink to pass — without any sensation to the patient. The therapy preserves the body's natural anatomy to reduce gastrointestinal side effects associated with traditional anti-reflux surgery.
Quantifiable outcome
- Resolution of regurgitation and heartburn in most patients
- +4 more outcomes
Companies that use EndoStim
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
EndoStim technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
EndoStim partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights4 records
EndoStim competitors and assessment
Company assessmentDirect peers
- Ethicon (Johnson & Johnson) — LINX Reflux Management System: Markets the LINX magnetic sphincter augmentation system, the most directly competing implantable device for refractory GERD. Targets the same patient population and specialist channel as EndoStim and is the primary incumbent benchmark EndoStim must displace.
- EndoGastric Solutions: Develops the EsophyX device for transoral incisionless fundoplication (TIF), a minimally invasive alternative for refractory GERD. Competes for the same anti-reflux procedure economics and gastroenterology/surgeon referral channel.
- Torax Medical (acquired by Ethicon): Originally developed the LINX system before acquisition by Ethicon — a successful exit path for a refractory-GERD implantable device company and a relevant comparator for EndoStim's strategic trajectory.
Emerging players
- Mederi Therapeutics (Stretta): Provides the Stretta radiofrequency system for endoscopic treatment of GERD. Competes in the refractory-GERD niche with a non-implant, endoscopic alternative — directly relevant to EndoStim's positioning discussion.
- CSA Medical: Develops interventional GI technologies (truFreeze/CryoSpray Ablation); an adjacent emerging player in therapeutic endoscopy/foregut intervention that targets a similar gastroenterologist buyer.
Broad incumbents
- Inspire Medical Systems: A commercial-stage implantable neurostim company (hypoglossal nerve stimulation for sleep apnea) that demonstrates the commercial pathway and reimbursement playbook relevant to EndoStim's launch model.
- Medtronic: Global medtech incumbent with the Enterra gastric neurostimulator for gastroparesis, providing a large-player reference point for GI neurostimulation regulation, clinical evidence expectations, and reimbursement.
- Axonics: Commercial-stage implantable neuromodulation company (sacral and tibial) with direct applicability to EndoStim's implantable-neurostim manufacturing, MRI-conditional labeling, and physician-training requirements.
- Boston Scientific: Major medtech incumbent and prior employer of EndoStim's CEO; broad gastroenterology and neuromodulation franchises make it the most relevant strategic-acquirer and large-player comparator.
- Abbott: Major neuromodulation incumbent (spinal cord stimulation, deep brain stimulation) with a relevant implantable-device commercial infrastructure and acquisition track record that EndoStim could attract.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
EndoStim social profiles
Digital presenceEndoStim financial estimates
Financial estimateRevenue estimate
Valuation estimate
EndoStim leadership team
Management profileNumber of profiles
Profiles6 records
EndoStim funding detail
Funding detailFunding overview
Funding rounds8 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EndoStim M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EndoStim
What does EndoStim do?
EndoStim develops the EndoStim System, a first-in-class implantable neurostimulation device that automatically delivers mild electrical signals throughout the day to the lower esophageal sphincter (LES) muscle to restore normal function and provide long-term reflux control for patients with drug refractory gastroesophageal reflux disease (GERD). The system is placed via a minimally-invasive laparoscopic procedure of approximately 1 hour, with 2 small electrodes on the lower esophagus and a neurostimulator positioned under the skin in the abdomen, and is programmed wirelessly by a physician using an external handheld controller. The device is not yet approved for sale in the US (limited to investigational use only) and is not commercially available in the EU or Latin America.
Is EndoStim a public or private company?
EndoStim is a private company. It is classified as venture growth investor backed and is currently operating.
When was EndoStim founded?
EndoStim was founded in 2009. It employs 11 to 50 people.
Where is EndoStim based?
EndoStim is headquartered in St Louis, United States, in the North America region.
How does EndoStim make money?
One revenue line is on record: medical Device Sales.
Who are EndoStim's main competitors?
Direct peers on record are Ethicon (Johnson & Johnson) — LINX Reflux Management System, EndoGastric Solutions and Torax Medical (acquired by Ethicon). Emerging players are Mederi Therapeutics (Stretta) and CSA Medical. Broad incumbents are Inspire Medical Systems, Medtronic, Axonics, Boston Scientific and Abbott.
Does EndoStim have an API?
No public API is recorded for EndoStim.
What industry is EndoStim in?
EndoStim's product category is Implantable Neurostimulation Medical Devices. Its primary akta.pro industry code is HLAKAEAA, General Gastroenterology, with a secondary code of HLAFAIAE, Endoscopy & GI Procedure Centers. Its NAICS code is 334510 and its SIC code is 3845.